My friends, there are a few inescapable truths:
- Pharma does not (often) buy "ideas", "frameworks" or "technologies". They buy revenue streams.
- From a Pharma perspective, buying a small Australian biotech costs - the (insignificant) purchase price, covering the risk of the key principles departing, linking into the research management structure, reputational risk, etc.
Phylogica is a discovery focused biotech with a platform technology. Pharma have them exactly where they want them:
Starved for capital (which is cheap for Pharma)
At their beck and call - Pharma has no problems getting the research initiatives they want for chump change.
Why would Pharma change this situation?
From a PYC holder's perspective:
- The current shareprice heavily discounts due to the uncertainties and does not adequately reflect the value of the framework.
- More money will need to be spent to fully develop the framework. We are a long way from significant drug royalties.
However, if they can reasonably achieve cash flow self-sustainability - this will be a fantastic company to hold.
- Forums
- ASX - By Stock
- Ann: Janssen Collaboration Expanded
My friends, there are a few inescapable truths:- Pharma does not...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PYC (ASX) to my watchlist
|
|||||
Last
11.5¢ |
Change
-0.005(4.17%) |
Mkt cap ! $536.5M |
Open | High | Low | Value | Volume |
12.0¢ | 12.5¢ | 11.5¢ | $383.6K | 3.159M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 410 | 11.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
10.5¢ | 413 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 412 | 0.115 |
6 | 179100 | 0.110 |
5 | 392419 | 0.105 |
10 | 839229 | 0.100 |
1 | 7221 | 0.099 |
Price($) | Vol. | No. |
---|---|---|
0.105 | 413 | 1 |
0.115 | 1549 | 1 |
0.120 | 1000000 | 2 |
0.125 | 49465 | 1 |
0.130 | 1325102 | 20 |
Last trade - 15.58pm 23/08/2024 (20 minute delay) ? |
Featured News
PYC (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online